key: cord-0906185-lazhcqza authors: Almadani, O.; Alshammari, T. M. title: Vaccine Adverse Event Reporting System (VAERS): Evaluation of 31 Years of Reports and Pandemics' Impact date: 2022-03-25 journal: nan DOI: 10.1101/2022.03.23.22272819 sha: 389eb87814532b837d8635326d5c62ca1241a099 doc_id: 906185 cord_uid: lazhcqza Background: Vaccine adverse event reporting system (VAERS) was established in the United States (U.S.) as an early warning system with a main purpose of collecting postmarketing adverse events following immunizations (AEFIs) reports to monitor the vaccine safety and to mitigate the risks from vaccines. During the coronavirus diseases 2019 (COVID-19) pandemic, VAERS got more attention as its important role in monitoring the safety of the vaccines. Thus, the aim of this study was to investigate VAERS patterns, reported AEFIs, adverse events of special interest (AESIs), impact of different pandemics since its inception, and surveillance rate of serious vs nonserious AEFIs. Methods: This was an observational study using VARES data from 2/7/1990 to 12/11/2021. Patterns of reports over years were first described, followed by a comparison of reports statistics per year. Furthermore, a comparison of incidents (death, ER visits, etc.) statistics over years, in addition to statistics of each vaccine were calculated. Moreover, each incident's statistics for each vaccine were calculated and top vaccines were reported. Finally, survival analysis utilizing cox regression was done, in addition to AESIs distribution stratified by age groups and gender. All analyses were conducted using R (Version 1.4.1717) and Excel for Microsoft 365. Results: There were 1,396,280 domestic and 346,210 non-domestic reports during 1990-2021, including 228 vaccines. For both domestic and non-domestic reports, year of 2021 had the highest reporting rate (48.52% and 70.33%), in addition a notable changes in AEFIs patterns were recorded during 1991, 1998, 2000, 2006, 2009, 2011, and 2017. AEFIs were as follow: deaths (1.00% and 4.08%), ER or doctor visits (13.37% and 2.27%), hospitalizations (5.84% and 27.78%), lethal threat (1.42% and 4.38%), and disabilities (1.4% and 7.96%). Pyrexia was the top reported symptom during the past 31 years, except for 2021 where headache was the top one. COVID-19 vaccines namely Moderna, Pfizer-Biontech, and Janssen were the top 3 reported vaccines with headache, pyrexia, and fatigue as the top associated AEFIs. Followed by Zoster, Seasonal Influenza, Pneumococcal, and Human papillomavirus vaccines. Myocarditis or Pericarditis were the top reported AESIs (26.95% and 25.84%). Male (HR:1.15, 1.14 - 1.16) for domestic (HR:1.23, 1.22 -1.25) for nondomestic have a higher probability of having serious AEFIs. In addition, age group [≤] 5 years old in domestic and >84 years old in nondomestic have a higher probability of having AEFIs compared to other age groups. Conclusions: The large data available in VARES make it a useful tool for detecting and monitoring vaccine AEFIs. However, its usability relies on understating the limitations of this surveillance system, the impact of governmental regulations, availability of vaccines, and public health recommendations on the reporting rate. This study includes data from VAERS, which is a passive AEFI reporting system that the USFDA and CDC established in 1990. These multidimensional data are reported by individual health care providers or the public when someone experiences an AEFI, without a confirmation of the AEFI's real cause. Data available on the website is formatted as ready-to-download comma-separated value (CSV) files, which can be imported to the CDC WONDER online search tool. VAERS data are available as domestic and nondomestic data. More than 99% of nondomestic data is reported by vaccine manufacturers. Furthermore, these data are divided for each year into three files: data, symptoms, and vaccine information. Table 1 presents variables available in VAERS data that we have used in this paper. The code of federal regulations (CFR) defines a lethal threat as any adverse event or condition that puts the patient or subject in immediate danger of death. In addition, it defines disability as a long-term or considerable inability or disturbance of the subject's ability to carry out normal life functions 7 . Moreover, an AESI is a condition or event that occurs in certain people after vaccination and has the potential to be causally linked to a vaccine [16] [17] [18] . AESIs we included in this study are anaphylaxis, appendicitis, bell's palsy, deep vein thrombosis (DVT), disseminated intravascular coagulation, encephalomyelitis, Guillain-Barré syndrome, immune thrombocytopenia, myocardial infarction, myocarditis or pericarditis, narcolepsy, pulmonary embolism, non-hemorrhagic or hemorrhagic stroke, and transverse myelitis [16] [17] [18] . VAERS data is multidimensional data, meaning one report may contain several symptoms or vaccines. First, for domestic data, we merged symptoms and vaccine files based on VAERS_ID. Then we separated reports containing multiple vaccines-because no clear information is available about which vaccine triggered those events-in a way that each vaccine reported in them presents the same event information. We followed the same steps with nondomestic files. Reprocessing completed using R studio (version 1.4.1717). We first described patterns of reports over the years by calculating the number of reports per year and then placing that number on a line chart. We then calculated a comparison of reports statistics per year as follows: Percentage of total reports in a year = We made these calculations and created these charts using Excel for Microsoft 365. We excluded 2019 coronavirus disease vaccines from the charts of the most common vaccine patterns due to their recent development. Moreover, we performed a survival (time to event) analysis, were individuals followed up from the vaccination date up to the event date (onset of AEFIs), using survival package in R studio 19 . Based on FDA protocol recommendation, we restrict follow up to 365 days 16, 20 . All data in . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 25, 2022. VAERS are for confirmed events, because of that we used non serious AEFIsinstead of no event -as a comparator to serious AEFIs to calculate the probability of survival 19 . Last, we calculated distribution of AESIs among all vaccines, and their distribution to COVID vaccines. Results: A. Domestic data: The number of reported hospitalizations is 81 538 (5.84%), with a continuous decrease in the hospitalization rates and the largest hospitalization rate occurring in 1990 (12.13%). Supplementary figure 6 shows pattern of domestic reported hospitalization over years. The highest number of average hospitalization days (mean = 12.7 days) occurred in 2021, compared to an average of hospitalization days of 6.3 over the past 30 years. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) figure 7 presents the top vaccines in terms of reported hospitalization. The number of reported lethal threats is 19 872 (1.42%), with the most lethal threats occurring in 1999 (2.56%), followed by 2.03% in 1995 and 2.00% in 1994. Supplementary figure 8 presents the pattern of reported lethal threats over years. COVID vaccines are the top vaccines in terms of lethal threats-Pfizer-Biontech (22.35%), Moderna (18.23%), and Janssen (6.04%)-followed by Fluzone (4.13%), Gardasil (3.76%), and seasonal influenza, no brand (2.21%). Supplementary figure 9 presents the top five vaccines in terms of reported lethal threats per years. In addition, supplementary table 6 presents the number of domestic reported lethal threats per vaccine per year. The total number of reported disabilities is 22 639 (1.4%), with the most frequently reported CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The total number of reported symptoms is 3 449 887. Table 8 lists the top vaccines in terms of reported symptoms. From 1990 through 2000, pyrexia was the most frequently reported AEFI (8.41%), followed by injection site hypersensitivity (4.29%), rash (3.36%), injection site edema (3.14%), and vasodilatation (2.88%). However, from 2001 through 2010, erythema was the most frequently reported AEFI (7.16%), followed by pyrexia (4.59%), injection site pain (4.57%), injection site swelling (2.55%), and rash (2.16%). Finally, from 2011 through 2020, pyrexia was the most frequently reported AEFI (3.33%), followed by injection site pain (2.85%), injection site erythema (2.73%), incorrect product storage (2.15%), and injection site swelling (2.04%). Table 9 presents the most frequently reported AEFIs and the associated vaccines. There were 346 210 nondomestic reports from 1990 through 2021. Reports included 214 vaccines. 2021 had the most reports (n = 243 500, 70.33%), followed by 2019 (n = 9,569, 2.76%), 2018 (n = 8,673, 2.512%), 2020 (n = 8,111, 2.34%), and 2016 (n = 7,991, 2.31%). Most of the sample (61.15%) came from female subjects, and the average age was 20.94 years. The top vaccine in terms of nondomestic reports is Pfizer-Biontech (57.64%), followed by Moderna (9.04%), Gardasil (2.57%), Janssen (2.48%), and seasonal influenza, no brand name (1.76%). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The total number of reported deaths is 14 125 (4.08%). The most deaths occurred in 1991 (10.17%), followed by 1993 (9.32%), 1994 (8.70%), 1990 (8.16%), and 1992 (8.00%). Supplementary figure 13 presents pattern of nondomestic reported death over years. The top vaccine in terms of reported deaths is Pfizer-Biontech (61.27%), followed by Moderna The total number of reported ER or doctor office visits is 7,868 (2.27%), with the most ER or The total number of reported disabilities is 27 545 (7.96%), with reported disabilities occurring . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 25, 2022. ; Pfizer-Biontech is the top vaccine in terms of nondomestic reported disabilities (59.52%), followed by Moderna (10.36%), Gardasil (4.76%), Engerix-B (3.42%), and Janssen (2.70%). The total number of nondomestic reported symptoms is 2 159 135. Table 15 reported AEFI was SARS-CoV-2 test (4.59%), followed by headache (3.18%), fatigue (2.57%), pyrexia (2.55%), and nausea (1.82%). Table 16 presents the most frequently reported AEFIs with the most frequently associated vaccines. Domestic reports with complete vaccination and onset data are 1 121 698, while for nondomestic data they are 262 723. Probability of having non serious AEFIs has its highest value at the vaccination's day, with 93% probability of having non serious AEFIs in domestic data, and 85.91% in nondomestic data. It continuously decreased after that to its minimal . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 25, 2022. ; 10.40% and 6.08% at the end of the following up window, for domestic and nondomestic data, respectively. However, for serious AEFIs they have a proportional relation to time, where they have their lowest values in the vaccination's day, ranging from 0.09% to 5.18% for domestic data and ranging from 0.39% to 8.00% for nondomestic data. For domestic data ER or Doctor visit was the highest serious AEFIs by 33.84%, and for nondomestic data hospitalization was the highest by 54.10% at the end of the follow up window. Out of 3 449 887 domestic reported symptoms 17 611 (0.51%) were AESIs, 9 665 (54.88%) were associated with COVID-19 vaccines. Table 19 shows distribution of domestic AESIs associated with COVID-19 stratified by gender and age. While for nondomestic reported symptoms out of 2 159 135 there were 35 810 (1.66%) AESIs, 31 511 (87.99%) were associated with COVID-19 vaccines. Table 20 shows distribution of nondomestic AESIs associated with COVID-19 stratified by gender and age. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 25, 2022. ; https://doi.org/10.1101/2022.03.23.22272819 doi: medRxiv preprint Vaccination saves 2.5 million children from death each year, according to WHO estimates [21] [22] [23] [24] . Moreover, it is the most effective technique for preventing infectious diseases and reducing their associated mortality and morbidity rate 21, 23, 24 . However, threatening factors associated with vaccinations, such as AEFIs, could have a negative impact on vaccination rates 21, 23 . Here, we describe VAERS data and evaluate their usability. We also examine COVID19's impact on the reporting patterns. The VAERS provides a wealth of information for analyzing AEFIs and their patterns over time 10, 12, 25 . Such a surveillance system with a large data set can be utilized for event detection and generation to investigate and evaluate vaccine safety, ultimately helping develop regulatory laws and actions to minimize the risks associated with these vaccines 10, [25] [26] [27] . Descriptive and pattern analysis of raw VAERS data combined with data visualization showed several intriguing patterns over the previous 31 years. This study's outcomes provide some insights into and can guide further research on certain vaccines and AEFIs. We found another interesting pattern described by an increase in nondomestic disabilities in . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 25, 2022. ; https://doi.org/10.1101/2022.03.23.22272819 doi: medRxiv preprint 1998, which was associated with a similar pattern in hepatitis B and MMR II vaccines. Wakefield study results may affect the reporting pattern of MMR. The outcome of this study, which was published in 1998, showed that a behavioral and development disorder in children resulted from MMR 52,53 . In the domestic and nondomestic data, pyrexia was the most frequently reported AEFI over the past 30 years. Pyrexia is defined as an elevation of body temperature that exceeds the normal range due to the presence of a foreign substance in the body 54 . This AEFI is expected as a part of the activated immune response 3,54-56 . However, in 2021, headache was the most frequently reported AEFI and was mainly associated with COVID-19 vaccines 3,55-58 . In the domestic data, injection site AEFIs were the most common 3, 55 . Furthermore, the nondomestic data shows a variety of symptoms, with vomiting being the commonly reported AEFI over the past 30 years 3,55,56 . CDC estimated 0.48 cases of myocarditis per 100,000 after COVID-19 vaccination, and in this study results of AESIs analysis show that most most reported adverse event associated with COVID-19 was myocarditis or pericarditis which support these results 59, 60 . Results of our study show that most of AEFIs are nonserious and more than 80% of them appear within first few days following vaccination, which is consistent with results found in other articles [61] [62] [63] . In addition, male and age group ≤ 5 years were more prone to serious AEFIs in consistent with findings from prior research 63, 64 . These findings could strengthen the argument for VARES's efficient use. Generally, stimulated reporting is noticeable in this study's outcomes 25, 26 . Yearly patterns were mostly affected by the USFDA's approval of vaccines such as the Lyme and HPV vaccines, CDC recommendations, such as administration of the H1N1 and DTP vaccines, and . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 25, 2022 Given that this is a passive reporting system, and that each report may contain information about several vaccines, we cannot confirm a causal relationship between a vaccine and its associated AEFIs 12, 25, 26 . Incomplete reports and underreporting are a noticeable issue in these data sets, which can be seen clearly with serious AEFIs. In addition, most of the nondomestic data are reported by manufacturers to fulfill legal requirements, which could lead to misleading selective reporting and thereby impact nondomestic data more than domestic data 25 . Although the VAERS uses MedDRA medical terminology, spelling mistakes and duplication (e.g., pyrexia and elevated body temperature) could have a negative impact on the data 12 . In conclusion, the VAERS is considered an important and useful tool in vaccine safety surveillance. However, the usability of VAERS data depends on users understating this surveillance system's limitations and knowing how to interpret its results. Governmental regulations, availability of vaccines, and public health recommendations have the largest impact on reporting rates, which could be used to improve VAERS data. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 25, 2022 RECVDATE Receiving data of the report, which has been converted to year. Age in years. Reported gender. Patient died following vaccination. L_THREAT Patient has life-threatening illness any time following vaccination. Patient visits ER any time following vaccination. Patient been hospitalized any time following vaccination. Patient has disability any time following vaccination. Adverse event as per MedDRA* * MedDRA is an international medical terminology. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 25, 2022. ; . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 25, 2022. ; https://doi.org/10.1101/2022.03.23.22272819 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 25, 2022. ; . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 25, 2022. ; . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 25, 2022 Vaccine and Related Biological Product Guidances | FDA Definition and Application of Terms for Vaccine Pharmacovigilance Regulation of Vaccines: Strengthening the Science Base CFR -Code of Federal Regulations Title 21 Food and Drug Administration Regulation and Evaluation of Vaccines abstract MODULE 1 -Pre-licensure vaccine safety -WHO Vaccine Safety Basics A statistical analysis of vaccine-adverse event data Fda, Cber. Contains Nonbinding Recommendations Emergency Use Authorization for Vaccines to Prevent COVID-19 Guidance for Industry Preface Public Comment COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years -United States Emergency Use Authorization for Vaccines Explained | FDA CBER Surveillance Program Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring Protocol Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study Survival analysis Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines BMC International Health and Human Rights Opinion Global immunization: status, progress, challenges and future Ten great public health achievements--United States, 1900-1999. MMWR Morbidity and mortality weekly report Human Vaccines & Immunotherapeutics Vaccine hesitancy An overview Revue des maladies respiratoires Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS) Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. The Pediatric infectious disease journal Understanding the Vaccine Adverse Event Reporting System (VAERS) What is a Serious Adverse Event? | FDA Safety profile of pneumococcal conjugate vaccines: systematic review of pre-and post-licensure data. Bulletin of the World Health Organization Human Vaccines 13-valent pneumococcal conjugate vaccine (PCV13) Pinkbook: Pneumococcal Disease | CDC Hospitalized Patients with 2009 H1N1 Influenza in the United States Influenza A (H1N1) Virus Infection H1N1 Pandemic (H1N1pdm09 virus) | Pandemic Influenza (Flu) | CDC Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports Updates on Influenza Vaccination in Children Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices About Diphtheria, Tetanus, and Pertussis Vaccination | CDC Ask the Experts about Pertussis Vaccines (DTaP, Tdap) -CDC experts answer Q&As Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males -Advisory Committee on Immunization Practices (ACIP) Quadrivalent Human Papillomavirus Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP). Accessed Fever after immunization: Current concepts and improved future scientific understanding The how's and what's of vaccine reactogenicity Vaccine Adverse Events: Separating Myth from Reality Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, openlabel, non-randomised, first-in-human trial Post-Vaccination Headache Reporting Trends According to the Vaccine Adverse Events Reporting System (VAERS) (P1.147) gov/coronavirus COVID-19 mRNA vaccines in adolescents and young adults: Benefit-risk discussion Myocarditis after Covid-19 Vaccination in a Large Health Care Organization Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy Assessment of sex-specific differences in adverse events following immunization reporting in Ontario